<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580006</url>
  </required_header>
  <id_info>
    <org_study_id>DA3285_SC_I</org_study_id>
    <nct_id>NCT02580006</nct_id>
  </id_info>
  <brief_title>To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study is to compare pharmacokinetics, safety and pharmacodynamics of EPORON and
      EPREX after single subcutaneous administration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve last(AUClast) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum of concentration(Cmax) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte count (%) compared to baseline</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 12, 24, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35), 216 (day 10/day 38), 312 (day 14/day 42) hrs after administration for each period</time_frame>
    <description>The absolute difference from the most increased case and its relative percentage (%) when comparing the results before administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration(Tmax) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life(t1/2) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve infinity(AUCinf) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance(CL/F) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time last(MRTlast) of Erythropoietin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 1, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 12, 24, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35), 216 (day 10/day 38), 312 (day 14/day 42) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 12, 24, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35), 216 (day 10/day 38), 312 (day 14/day 42) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC count</measure>
    <time_frame>Twice every 10 minutes within 1hr before administration (day 1/day 29); immediately before administration; 12, 24, 48, 72, 96, 120 (day 6/day 34), 144 (day 7/day 35), 216 (day 10/day 38), 312 (day 14/day 42) hrs after administration for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EPORON→EPREX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPREX→EPORON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPORON</intervention_name>
    <description>single dose administration subcutaneously</description>
    <arm_group_label>EPORON→EPREX</arm_group_label>
    <arm_group_label>EPREX→EPORON</arm_group_label>
    <other_name>EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPREX</intervention_name>
    <description>single dose administration subcutaneously</description>
    <arm_group_label>EPORON→EPREX</arm_group_label>
    <arm_group_label>EPREX→EPORON</arm_group_label>
    <other_name>EPREX INJ. 4000 IU (Erythropoietin alfa 4000 IU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers between the ages of 19~50 at the time of screening

          -  Weight between 55.0kg~90.0kg with BMI of 18.0~27.0

          -  Voluntarily participants who agree to observe the precautions in writing after
             receiving a complete explanation of this trial

        Exclusion Criteria:

          -  History of clinically significant illness related to liver (including viral
             hepatitis), kidney, nervous system, immune system, respiratory system, endocrine
             system, cardiovascular system, blood system and tumor as well as mental illness (mood
             disorder, obsessive-compulsive disorder, etc.)

          -  Hypersensitivity or clinically significant hypersensitivity to the drug (e.g. aspirin,
             antibiotics, etc.)

          -  Those whose results meet more than one of the followings in the screening including
             re-test; Hemoglobin level below 12g/dL or over 17g/dL, Vitamin B12 level below
             200pg/mL, Ferritin level below 21.8ng/mL, Transferrin level below 190mg/dL,
             Reticulocyte, erythrocytes, platelets or serum potassium level over normal range

          -  Positive on the HIV antibody, HBsAg, HCV(Hepatitis C Virus) antibody tests

          -  Those whose vital signs measured in sitting position after resting over 3 minutes meet
             more than one of the following; Systolic BP below 90mmgHg or over 160mmgHg, Diastolic
             BP below 50mmgHg or over 100mmgHg, Pulse rate over 100

          -  History of drug abuse, or tested positive in the urine drug screening

          -  Administration of EPO(erythropoietin), darbepoetin or other EPO protein supply,
             immunoglobulin within 3 months from the scheduled first dose

          -  Hypersensitivity to EPO, darbepoetin or excipient in the test drug or anaphylactic
             reaction towards iron supplement

          -  Those who received the following diagnosis within 6 months from the screening;
             Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all kinds),
             Chronic or uncontrollable inflammatory diseases (e.g., rheumatoid arthritis, systemic
             erythematosus)

          -  Those who took any ETC(Ethical) drugs or herbal medicine within 2 weeks, or any
             OTC(Over-the-counter) drugs or vitamins within a week from the scheduled first dose
             (However, they may be included as the trial subjects at the discretion of the
             investigator if other conditions are satisfactory.)

          -  Those who participated other clinical trials and was administered other drugs within 3
             months from the scheduled first dose

          -  Those who bled over 400mL or donated blood within 8 weeks from the scheduled first
             dose

          -  Those who have continued drinking (exceeding 21 units/week, 1 unit = 10g of pure
             alcohol) or who can't abstain from alcohol during the trial period

          -  Those who have smoked over 10 cigarettes daily in average for the last 3 months or who
             can't renounce smoking during the trial period

          -  Those who have ingested grapefruit or caffeine containing food within 3 days from the
             scheduled first dose or who can't abstain from the during the trial period.

          -  Those who are preparing for pregnancy or who do not agree with contraception during
             the trial period

          -  Those with peculiar eating habits or who can't have meals provided by the hospital

          -  Those who are considered inappropriate for the trial by the trial investigator based
             on the result of clinical laboratory test or due to other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-sang Yu, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-jin Jang, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung-gi Lee, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ju-yeon Cho, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-hwan Lee, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital Clinical Trials Center / Clinical Pharmacology of Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-sang Yu, MD, Ph.D</last_name>
    <phone>82-02-2072-1920</phone>
    <email>ksyu@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trials Center</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyung-sant Yu, MD, Ph.D</last_name>
      <phone>82-02-2072-1920</phone>
      <email>ksyu@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

